Shopping Cart 0
Cart Subtotal
USD 0

Aptose Biosciences Inc (APTO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company which focuses on diagnostics, therapies and treatment for patients with life-threatening cancers. The company advances in new therapeutics which focuses on cellular targets of cancer research coupled with companion diagnostics to identify patient with cancer. Its small molecule cancer therapeutics pipeline includes products which are designed to provide single agent efficacy and efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The company's product portfolio comprises of CG'806, is a non-covalent small molecule therapeutic agent. Aptose is headquartered in Toronto, Ontario, Canada.

Aptose Biosciences Inc (APTO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aptose Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 11

Private Equity 11

Aptose Biosciences to Raise up to USD20 Million in Financing 11

Partnerships 13

Aptose Biosciences Enters into Agreement with Laxai Avanti Life Sciences 13

Lorus Therapeutics Enters Into Agreement With Brock University To Develop Novel Anticancer Drugs 14

Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 15

Licensing Agreements 17

Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 17

OHM Oncology Enters into Licensing Agreement with Aptose Biosciences 18

Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 19

Equity Offering 20

Aptose Biosciences Files Shelf Prospectus to Raise up to USD100 Million in Public Offering of Shares 20

Aptose Biosciences Raises Funds through Public Offering of Shares 21

Lorus Therapeutics Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For USD 25.3 Million 22

Lorus Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For USD 7.7 Million 24

Lorus Therapeutics Completes Private Placement Of Units For USD 0.9 Million 26

Lorus Therapeutics Completes Private Placement Of Units For USD 6.6 Million 27

Aptose Biosciences Inc-Key Competitors 29

Aptose Biosciences Inc-Key Employees 30

Aptose Biosciences Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Financial Announcements 32

Nov 06, 2018: Aptose reports results for the third quarter ended september 30, 2018 32

Aug 07, 2018: Aptose reports results for the second quarter ended june 30, 2018 35

May 10, 2018: Aptose Reports Results for the First Quarter Ended March 31, 2018 37

Mar 27, 2018: Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2017 39

Nov 14, 2017: Aptose Reports Results for the Third Quarter Ended September 30, 2017 41

Aug 08, 2017: Aptose Reports Results for the Second Quarter Ended June 30, 2017 43

May 11, 2017: Aptose Reports Results for the First Quarter Ended March 31, 2017 45

Mar 28, 2017: Aptose Reports Fourth Quarter and Year End 2016 Results 47

Corporate Communications 51

Aug 15, 2018: Aptose Biosciences appoints Carol Ashe as Board Director 51

Apr 25, 2018: Aptose Names Caroline M. Loewy As Board Director 52

Mar 27, 2017: Aptose Announces Planned Departure of Chief Business Officer 53

Legal and Regulatory 54

Feb 07, 2018: Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base Prospectus 54

Product Approvals 55

Jun 29, 2018: FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers 55

Clinical Trials 56

Jun 04, 2018: Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253 56

Apr 17, 2018: Aptose Presents Preclinical Data on APTO-253 at 2018 AACR Annual Meeting 57

Mar 15, 2018: Aptose to Present Preclinical Data of APTO-253 at the 2018 AACR Annual Meeting 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aptose Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aptose Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aptose Biosciences to Raise up to USD20 Million in Financing 11

Aptose Biosciences Enters into Agreement with Laxai Avanti Life Sciences 13

Lorus Therapeutics Enters Into Agreement With Brock University To Develop Novel Anticancer Drugs 14

Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 15

Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 17

OHM Oncology Enters into Licensing Agreement with Aptose Biosciences 18

Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 19

Aptose Biosciences Files Shelf Prospectus to Raise up to USD100 Million in Public Offering of Shares 20

Aptose Biosciences Raises Funds through Public Offering of Shares 21

Lorus Therapeutics Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For USD 25.3 Million 22

Lorus Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For USD 7.7 Million 24

Lorus Therapeutics Completes Private Placement Of Units For USD 0.9 Million 26

Lorus Therapeutics Completes Private Placement Of Units For USD 6.6 Million 27

Aptose Biosciences Inc, Key Competitors 29

Aptose Biosciences Inc, Key Employees 30

Aptose Biosciences Inc, Other Locations 31

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Aptose Biosciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company which focuses on diagnostics, therapies and treatment for patients with life-threatening cancers. The company advances in new therapeutics which focuses on cellular targets of cancer research coupled with companion diagnostics to identify patient with cancer. Its small molecule cancer therapeutics pipeline includes products which are designed to provide single agent efficacy and efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The company's product portfolio comprises of CG'806, is a non-covalent small molecule therapeutic agent. Aptose is headquartered in Toronto, Ontario, Canada.

Aptose Biosciences Inc (APTO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aptose Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 11

Private Equity 11

Aptose Biosciences to Raise up to USD20 Million in Financing 11

Partnerships 13

Aptose Biosciences Enters into Agreement with Laxai Avanti Life Sciences 13

Lorus Therapeutics Enters Into Agreement With Brock University To Develop Novel Anticancer Drugs 14

Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 15

Licensing Agreements 17

Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 17

OHM Oncology Enters into Licensing Agreement with Aptose Biosciences 18

Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 19

Equity Offering 20

Aptose Biosciences Files Shelf Prospectus to Raise up to USD100 Million in Public Offering of Shares 20

Aptose Biosciences Raises Funds through Public Offering of Shares 21

Lorus Therapeutics Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For USD 25.3 Million 22

Lorus Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For USD 7.7 Million 24

Lorus Therapeutics Completes Private Placement Of Units For USD 0.9 Million 26

Lorus Therapeutics Completes Private Placement Of Units For USD 6.6 Million 27

Aptose Biosciences Inc-Key Competitors 29

Aptose Biosciences Inc-Key Employees 30

Aptose Biosciences Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Financial Announcements 32

Nov 06, 2018: Aptose reports results for the third quarter ended september 30, 2018 32

Aug 07, 2018: Aptose reports results for the second quarter ended june 30, 2018 35

May 10, 2018: Aptose Reports Results for the First Quarter Ended March 31, 2018 37

Mar 27, 2018: Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2017 39

Nov 14, 2017: Aptose Reports Results for the Third Quarter Ended September 30, 2017 41

Aug 08, 2017: Aptose Reports Results for the Second Quarter Ended June 30, 2017 43

May 11, 2017: Aptose Reports Results for the First Quarter Ended March 31, 2017 45

Mar 28, 2017: Aptose Reports Fourth Quarter and Year End 2016 Results 47

Corporate Communications 51

Aug 15, 2018: Aptose Biosciences appoints Carol Ashe as Board Director 51

Apr 25, 2018: Aptose Names Caroline M. Loewy As Board Director 52

Mar 27, 2017: Aptose Announces Planned Departure of Chief Business Officer 53

Legal and Regulatory 54

Feb 07, 2018: Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base Prospectus 54

Product Approvals 55

Jun 29, 2018: FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers 55

Clinical Trials 56

Jun 04, 2018: Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253 56

Apr 17, 2018: Aptose Presents Preclinical Data on APTO-253 at 2018 AACR Annual Meeting 57

Mar 15, 2018: Aptose to Present Preclinical Data of APTO-253 at the 2018 AACR Annual Meeting 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aptose Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aptose Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aptose Biosciences to Raise up to USD20 Million in Financing 11

Aptose Biosciences Enters into Agreement with Laxai Avanti Life Sciences 13

Lorus Therapeutics Enters Into Agreement With Brock University To Develop Novel Anticancer Drugs 14

Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 15

Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 17

OHM Oncology Enters into Licensing Agreement with Aptose Biosciences 18

Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 19

Aptose Biosciences Files Shelf Prospectus to Raise up to USD100 Million in Public Offering of Shares 20

Aptose Biosciences Raises Funds through Public Offering of Shares 21

Lorus Therapeutics Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For USD 25.3 Million 22

Lorus Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For USD 7.7 Million 24

Lorus Therapeutics Completes Private Placement Of Units For USD 0.9 Million 26

Lorus Therapeutics Completes Private Placement Of Units For USD 6.6 Million 27

Aptose Biosciences Inc, Key Competitors 29

Aptose Biosciences Inc, Key Employees 30

Aptose Biosciences Inc, Other Locations 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Aptose Biosciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.